Dominance of the hypothalamus-pituitary-adrenal axis over the renin-angiotensin-aldosterone system is a risk factor for decreased insulin secretion

[1]  S. Suh,et al.  Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem , 2017, Endocrinology and metabolism.

[2]  J. Tanabe,et al.  Association between Higher Serum Cortisol Levels and Decreased Insulin Secretion in a General Population , 2016, PloS one.

[3]  A. Rafacho,et al.  Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence , 2016, Metabolites.

[4]  W. Langhans,et al.  Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4 , 2016, Molecular metabolism.

[5]  T. Heise,et al.  Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks , 2016, Diabetes, obesity & metabolism.

[6]  A. Boschero,et al.  Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  H. Murakami,et al.  Association Between Pituitary-Adrenal Axis Dominance Over the Renin-Angiotensin-Aldosterone System and Hypertension. , 2016, The Journal of clinical endocrinology and metabolism.

[8]  H. Yamashita,et al.  Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study. , 2015, Journal of atherosclerosis and thrombosis.

[9]  I. Quesada,et al.  Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. , 2014, The Journal of endocrinology.

[10]  T. Heise,et al.  Safety, efficacy and weight effect of two 11β‐HSD1 inhibitors in metformin‐treated patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[11]  W. Bollag.  Regulation of aldosterone synthesis and secretion. , 2014, Comprehensive Physiology.

[12]  M. Woodward,et al.  Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus: The ADVANCE Trial , 2013, Circulation.

[13]  T. Ninomiya,et al.  Secular Trends in Cardiovascular Disease and Its Risk Factors in Japanese: Half-Century Data From the Hisayama Study (1961–2009) , 2013, Circulation.

[14]  G. Marek,et al.  Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT‐384 in Healthy Volunteers and Elderly Adults , 2013, Clinical pharmacology in drug development.

[15]  F. Beuschlein,et al.  Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[16]  Masahiko Kato,et al.  20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report , 2013, Cardiovascular Diabetology.

[17]  F. Jaisser,et al.  Novel Transgenic Mice for Inducible Gene Overexpression in Pancreatic Cells Define Glucocorticoid Receptor-Mediated Regulations of Beta Cells , 2012, PloS one.

[18]  S. Yusuf,et al.  Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. , 2011, European heart journal.

[19]  E. Lai,et al.  Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome , 2011, Diabetes, obesity & metabolism.

[20]  Norio Sugawara,et al.  Prevalence of metabolic syndrome among patients with schizophrenia in Japan , 2010, Schizophrenia Research.

[21]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[22]  J. Rosenstock,et al.  The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy , 2010, Diabetes Care.

[23]  P. Hopkins,et al.  Aldosterone production and insulin resistance in healthy adults. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[25]  W. Young,et al.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[27]  B. Ahrén.  Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans , 2008, Diabetologia.

[28]  O. Steichen.  A possible association between primary aldosteronism and a lower beta-cell function. , 2008, Journal of hypertension.

[29]  C. Carvajal,et al.  A possible association between primary aldosteronism and a lower β-cell function , 2007 .

[30]  M. Weir,et al.  Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? , 2007, Clinical therapeutics.

[31]  P. Mehta,et al.  Effects of Chronic Glucocorticoid Administration on Insulin-Degrading Enzyme and Amyloid-Beta Peptide in the Aged Macaque , 2005, Journal of neuropathology and experimental neurology.

[32]  S. Takagi,et al.  Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. , 2004, Atherosclerosis.

[33]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[34]  M. Igarashi,et al.  Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. , 2003, Diabetes care.

[35]  Khusru Asadullah,et al.  Mechanisms involved in the side effects of glucocorticoids. , 2002, Pharmacology & therapeutics.

[36]  P. Björntorp,et al.  Neuroendocrine abnormalities in visceral obesity , 2000, International Journal of Obesity.

[37]  P. Björntorp,et al.  Blood pressure in relation to obesity, insulin and the hypothalamic‐pituitary‐adrenal axis in Swedish men , 1998, Journal of hypertension.

[38]  P. Schneiter,et al.  Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. , 1998, American journal of physiology. Endocrinology and metabolism.

[39]  C. Wilson,et al.  Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. , 1998, Metabolism: clinical and experimental.

[40]  C. Östenson,et al.  Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. , 1997, The Journal of clinical investigation.

[41]  P. Gilon,et al.  Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. , 1997, The Journal of clinical investigation.

[42]  S. Weinstein,et al.  Glucocorticoid-Induced Insulin Resistance: Dexamethasone Inhibits the Activation of Glucose Transport in Rat Skeletal Muscle by Both Insulin- and Non-Insulin-Related Stimuli , 1995, Diabetes.

[43]  G. Chrousos,et al.  The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. , 1992, JAMA.

[44]  J. Halter,et al.  Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. , 1984, The American journal of physiology.

[45]  H. P. Fletcher,et al.  Insulin release after acute hydrocortisone treatment in mice. , 1983, Metabolism: clinical and experimental.

[46]  W. Dahms,et al.  Endocrine function in human obesity. , 1981, Metabolism: clinical and experimental.

[47]  M. Sherman,et al.  A Preliminary Report , 1953 .